175 related articles for article (PubMed ID: 15752382)
1. A predictive model for exemestane pharmacokinetics/pharmacodynamics incorporating the effect of food and formulation.
Valle M; Di Salle E; Jannuzzo MG; Poggesi I; Rocchetti M; Spinelli R; Verotta D
Br J Clin Pharmacol; 2005 Mar; 59(3):355-64. PubMed ID: 15752382
[TBL] [Abstract][Full Text] [Related]
2. [Phase I single-dose administration study of exemestane in postmenopausal women].
Miura S; Tominaga T; Koyama H; Nomura Y; Tsuboi M
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1179-87. PubMed ID: 12145999
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and dose finding of a potent aromatase inhibitor, aromasin (exemestane), in young males.
Mauras N; Lima J; Patel D; Rini A; di Salle E; Kwok A; Lippe B
J Clin Endocrinol Metab; 2003 Dec; 88(12):5951-6. PubMed ID: 14671195
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and tolerability of exemestane in combination with raloxifene in postmenopausal women with a history of breast cancer.
Traina TA; Poggesi I; Robson M; Asnis A; Duncan BA; Heerdt A; Dang C; Lake D; Moasser M; Panageas K; Borgen P; Norton L; Hudis C; Dickler MN
Breast Cancer Res Treat; 2008 Sep; 111(2):377-88. PubMed ID: 17952589
[TBL] [Abstract][Full Text] [Related]
5. Pilot study evaluating the pharmacokinetics, pharmacodynamics, and safety of the combination of exemestane and tamoxifen.
Rivera E; Valero V; Francis D; Asnis AG; Schaaf LJ; Duncan B; Hortobagyi GN
Clin Cancer Res; 2004 Mar; 10(6):1943-8. PubMed ID: 15041710
[TBL] [Abstract][Full Text] [Related]
6. [Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents].
Watanabe T; Sano M; Toi M; Saeki T; Kanda K; Miura S; Inaji H; Sono H; Saeki H; Nishimura R; Fujita Y
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1211-21. PubMed ID: 12146002
[TBL] [Abstract][Full Text] [Related]
7. Effect of Aromatase Inhibition (Exemestane) on Urine Concentration of Osteoprotegerin in Healthy Postmenopausal Women.
Garcia AP; Hatvany JB; Murphy MA; Atchley DH; Gurley BJ; Kamdem LK
J Clin Pharmacol; 2020 Feb; 60(2):209-217. PubMed ID: 31535401
[TBL] [Abstract][Full Text] [Related]
8. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
9. Oral bioavailability enhancement of exemestane from self-microemulsifying drug delivery system (SMEDDS).
Singh AK; Chaurasiya A; Awasthi A; Mishra G; Asati D; Khar RK; Mukherjee R
AAPS PharmSciTech; 2009; 10(3):906-16. PubMed ID: 19609837
[TBL] [Abstract][Full Text] [Related]
10. Endocrine and clinical effects of exemestane (PNU 155971), a novel steroidal aromatase inhibitor, in postmenopausal breast cancer patients: a phase I study.
Johannessen DC; Engan T; Di Salle E; Zurlo MG; Paolini J; Ornati G; Piscitelli G; Kvinnsland S; Lonning PE
Clin Cancer Res; 1997 Jul; 3(7):1101-8. PubMed ID: 9815789
[TBL] [Abstract][Full Text] [Related]
11. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane.
Buzdar AU; Robertson JF; Eiermann W; Nabholtz JM
Cancer; 2002 Nov; 95(9):2006-16. PubMed ID: 12404296
[TBL] [Abstract][Full Text] [Related]
12. The minimal effective exemestane dose for endocrine activity in advanced breast cancer.
Bajetta E; Zilembo N; Noberasco C; Martinetti A; Mariani L; Ferrari L; Buzzoni R; Greco M; Bartoli C; Spagnoli I; Danesini GM; Artale S; Paolini J
Eur J Cancer; 1997 Apr; 33(4):587-91. PubMed ID: 9274439
[TBL] [Abstract][Full Text] [Related]
13. Effects of exemestane and letrozole therapy on plasma concentrations of estrogens in a randomized trial of postmenopausal women with breast cancer.
Robarge JD; Desta Z; Nguyen AT; Li L; Hertz D; Rae JM; Hayes DF; Storniolo AM; Stearns V; Flockhart DA; Skaar TC; Henry NL
Breast Cancer Res Treat; 2017 Feb; 161(3):453-461. PubMed ID: 27943008
[TBL] [Abstract][Full Text] [Related]
14. Experience with exemestane in the treatment of early and advanced breast cancer.
Lønning PE; Geisler J
Expert Opin Drug Metab Toxicol; 2008 Jul; 4(7):987-97. PubMed ID: 18624685
[TBL] [Abstract][Full Text] [Related]
15. Exemestane: a review of its use in postmenopausal women with advanced breast cancer.
Clemett D; Lamb HM
Drugs; 2000 Jun; 59(6):1279-96. PubMed ID: 10882163
[TBL] [Abstract][Full Text] [Related]
16. Effect of exemestane on tamoxifen pharmacokinetics in postmenopausal women treated for breast cancer.
Hutson PR; Love RR; Havighurst TC; Rogers E; Cleary JF
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8722-7. PubMed ID: 16361559
[TBL] [Abstract][Full Text] [Related]
17. Impact of the OATP1B1 c.521T>C single nucleotide polymorphism on the pharmacokinetics of exemestane in healthy post-menopausal female volunteers.
Gregory BJ; Chen SM; Murphy MA; Atchley DH; Kamdem LK
J Clin Pharm Ther; 2017 Oct; 42(5):547-553. PubMed ID: 28868654
[TBL] [Abstract][Full Text] [Related]
18. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
19. Exemestane: a review of its use in postmenopausal women with breast cancer.
Deeks ED; Scott LJ
Drugs; 2009; 69(7):889-918. PubMed ID: 19441873
[TBL] [Abstract][Full Text] [Related]
20. Exemestane (FCE 24304), a new steroidal aromatase inhibitor.
di Salle E; Ornati G; Giudici D; Lassus M; Evans TR; Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):137-43. PubMed ID: 1525055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
